5AM Venture Management LLC of Menlo Park and Boston is pleased to announce the addition of the following three members to the firm:

David Allison, Ph.D. has joined as Principal,

Joe Victor has joined as Venture Partner, and

Rebecca Lucia, CFA has joined as Chief Financial Officer.

Dr. Allison brings extensive experience in life science venture capital and joins 5AM as a Principal in the Bay Area. “We have enjoyed working with David as a co-investor and syndicate partner over the past few years and we are delighted that he has joined the firm,” said Scott Rocklage, Managing Partner. “David’s strong scientific background, combined with sound investment acumen, makes him an ideal addition to the 5AM investment team.”

Dr. Allison joined 5AM’s Menlo Park office from Versant Ventures, where he was a Principal focused on biotechnology and other healthcare investments. Prior to Versant, Dr. Allison was a Principal at Split Rock Ventures and was previously a Senior Associate at PTV Healthcare Capital.

During his career, Dr. Allison has been actively involved in investments in biotechnology companies such as Aprea Therapeutics, Biotie Therapies (acquired by Acorda), Crinetics Pharmaceuticals, and Histogenics (Nasdaq: HSGX). In addition, he was involved in investments in Ardian (acquired by Medtronic) and RF Surgical Systems (acquired by Medtronic). Previously, Dr. Allison also spent time with SurModics and as an NSF Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory. Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix Mechanics in Cardiovascular Disease. He received a B.S. in Biomedical Engineering from The University of Iowa. Mr. Victor is based in 5AM’s Menlo Park, CA office and brings over 30 years of leadership experience fostering product innovation and building value in scientific research tool companies.

“I am proud to announce that Joe, former CEO of 5AM portfolio companies DVS Sciences (acquired by Fluidigm) and Startide Sciences, has joined the 5AM team as Venture Partner,” said Andy Schwab, Managing Partner. “Joe brings extensive operating knowledge and a history of value creation and we look forward to continuing a great working relationship.”

Prior to Startide Sciences and DVS Sciences, Mr. Victor served as CEO of Applied Precision (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of Biodesy, Precision Nanosystems, and Purigen Biosystems as well as on the Boards of Glencoe Software, and RareCyte. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor has also held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Rebecca Lucia joined 5AM’s Menlo Park office as Chief Financial Officer from Prospect Venture Partners, a life science-focused venture capital firm. “We are pleased to add Rebecca to our professional team.” said Paul Stone, Partner. “Her 20 years of experience in venture capital, finance, and in the life sciences industry will add significant value to both the investment and operational sides of our business.” Previously, Ms. Lucia served as CFO for Asset Management Ventures. She also held senior finance and investor relations positionsin the life science industry, including at CV Therapeutics and Chiron Corporation. She began her career at Deloitte where she was most recently a Senior Manager in the San Francisco Financial Advisory Services group. Ms. Lucia received an MBA from Kellogg School of Management and earned a Chartered Financial Analyst (“CFA”) designation as well as a Canadian Chartered Accountant (“CA”) designation.

About 5AM Ventures

Founded in 2002, 5AM actively invests in next-generation life science companies. With ~$1 billion under management, 5AM has invested in 55 companies and successful exits include Audentes Therapeutics (Nasdaq: BOLD), Cidara Therapeutics (Nasdaq: CDTX), DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (Nasdaq: RLYP, acquired by Galenica). For more information, please visit www.5amventures.com.